You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Article info

Article menu

Download PDFPDF

XML
Immunotherapy biomarkers
Original research
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Authors

  • Jacqueline T Brown Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Yuan Liu Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartments of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Julie M Shabto Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Dylan Martini Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Deepak Ravindranathan Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Emilie Elise Hitron Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Greta Anne Russler Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Sarah Caulfield Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Pharmaceutical Services, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Lauren Yantorni Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Shreyas Subhash Joshi Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Urology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Haydn Kissick Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Urology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Kenneth Ogan Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Urology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Bassel Nazha Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Bradley C Carthon Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Omer Kucuk Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Wayne B Harris Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Viraj A Master Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Urology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Mehmet Asim Bilen Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Mehmet Asim Bilen; mehmet.a.bilen{at}emory.edu
View Full Text

Citation

Brown JT, Liu Y, Shabto JM, et al
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer 2021;9:e002851. doi: 10.1136/jitc-2021-002851

Publication history

  • Accepted May 24, 2021
  • First published July 29, 2021.
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.